RxDoctor Payments Data

Aryan Mashid, OD

Optometrist · Sterling, VANPI 1902274574

Payments from drug & device makers

$4,013in general payments, 2019–2025

Across 174 payments — averaging $23.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sun Pharmaceutical Industries Inc.$1K
  • AbbVie$924
  • Tarsus Pharmaceuticals, Inc.$389
  • Oyster Point Pharma, Inc.$263
  • Novartis$242
  • Carl Zeiss Meditec USA, Inc.$195
  • plus $954 from 12 others

What the payments were for

  • Food & beverage$3,81895%
  • Other$1955%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,013 in reported general payments places this provider in the 85th percentile of 1,230 optometrist providers in Virginia.

See all optometrist providers in Virginia

Medicare billing

Part B allowed, 2024
$76,754
Medicare patients
277
Services billed
1,042

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine110$140,792
LumiganBimatoprost43$20,563
Cyclosporine27$12,635
XiidraLifitegrast11$12,271
Travoprost22$6,936
Brimonidine Tartrate32$3,729
Tobramycin-DexamethasoneTobramycin/Dexamethasone72$3,032
Azelastine Hcl74$2,851
Loteprednol Etabonate12$2,073
Latanoprost133$1,530
MoxifloxacinMoxifloxacin Hcl35$1,201
Fluorometholone18$848
Timolol Maleate23$594
Dorzolamide Hcl18$500
Prednisolone Acetate13$496

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$924$161,355153 claims
Bausch & Lomb Americas Inc.Xiidra$181$12,27111 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$60$2,07312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,230 optometrist providers in Virginia.

Other optometrist in Sterling

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →